Argos Therapeutics, Inc. (ARGS)

Oncology Corporate Profile

Stock Performance


3 Month Stock History Chart

Data provided for free by IEX.

HQ Location

4233 Technology Drive
Durham, NC 27704

Company Description

Argos Therapeutics, Inc. is developing breakthrough immunotherapies that target unique features of a patient's disease. This new generation of personalized cancer and infectious disease therapeutics trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Arcelis® / AGS-003immunotherapy (RNA-loaded DC)1st line metastatic Renal cell carcinoma (RCC)II
Arcelis® / AGS-003immunotherapy (RNA-loaded DC)Non Small Cell Lung Cancer (NSCLC)II
Arcelis® / AGS-003immunotherapy (RNA-loaded DC)Various cancer typesII

View additional information on product candidates here »


Recent News Headlines

Argos Therapeutics Enters into Strategic Research Agreement with Adaptive Biotechnologies

6/15/2016 05:09 pm

(NASDAQ) June 15, 2016 - Argos Therapeutics, Inc. today announced that it is partnering with Adaptive Biotechnologies Corporation, based in Seattle, Washington, to study precise response patterns to Argos’ investigational immunotherapies.

Argos Lays Off 18 and Executive Resigns, But Phase 3 Still on Track

4/21/2016 04:37 pm

(Xconomy Raleigh-Durham) Apr 20, 2016 - Argos Therapeutics has already secured financing expected to carry the company far enough to report late-stage clinical trial results for its experimental kidney cancer treatment, but that hasn’t stopped the company from taking additional cost-cutting measures.

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy

3/23/2016 03:56 pm

(StreetInsider) Mar 23, 2016 - Argos Therapeutics, Inc. today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).

Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia

3/3/2016 11:03 am

(TheStreet) Mar 3, 2016 - Bio-Path Holdings, Inc today announced positive results from the eighth and final cohort of the safety segment of Bio-Path’s Phase II trial assessing the toxicity of the Company’s lead product candidate, BP1001 (Liposomal Grb2 antisense), in combination with low-dose cytarabine (LDAC) chemotherapy in patients with advanced acute myeloid leukemia (AML).

On Comeback Trail, Exelixis Reels In $200M Deal For Cancer Drug

3/1/2016 11:04 am

(Xconomy San Francisco) Feb 29, 2016 — Cancer drug developer Exelixis continued its comeback, announcing Monday a deal with Ipsen that will pay the South San Francisco, CA-based biotech $200 million upfront.

AstraZeneca Reports Top-Line Result Of Tremelimumab Monotherapy Trial In Mesothelioma

2/29/2016 12:00 pm

(AstraZeneca) Feb 29, 2016 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced that DETERMINE, the Phase IIb clinical trial of 10 mg/kg tremelimumab monotherapy in second or third-line treatment of unresectable malignant mesothelioma, did not meet its primary endpoint of overall survival.

Zafgen Says Patient Died In Clinical Trial Of Obesity Drug

10/15/2015 12:02 pm

(Boston Globe) Oct 14, 2015 - Zafgen Inc., a Boston biotech company developing treatments for obesity and metabolic disorders, said Wednesday that it was investigating the death of a patient who was participating in a late-stage clinical trial of its lead drug candidate.

Dietary Supplements Lead to 20,000 E.R. Visits Yearly, Study Finds

10/15/2015 12:01 pm

(New York Times/Well blog) Oct 14, 2015 - A large new study by the federal government found that injuries caused by dietary supplements lead to more than 20,000 emergency room visits a year, many involving young adults with cardiovascular problems after taking supplements marketed for weight loss and energy enhancement.

FDA Declines to Expand Approval of Pfizer Arthritis Drug

10/15/2015 12:01 pm

(Reuters) Oct 14, 2015 - U.S. health regulators declined to approve Pfizer Inc's oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday.

Valeant Subpoenaed Over Patient Assistance Program, Pricing

10/15/2015 12:01 pm

(ABC/Associated Press) Oct 14, 2015 - Valeant Pharmaceuticals International Inc. says that federal prosecutors have subpoenaed the drug developer, seeking information on its drug pricing, distribution and patient assistance program.

WSJ Report: Theranos Is Struggling With Its Blood Test Technology

10/15/2015 12:01 pm

(Fortune) Oct 15, 2015 - Is Theranos as great as it seems?

Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications

10/15/2015 12:00 pm

(CNN Money) Oct 15, 2015 - COMP opinions recommend EU orphan designation for the treatment of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL).

OHSU Releases Mole Mapper ResearchKit App to Track Potential Skin Cancers

10/15/2015 12:00 pm

(OHSU) Oct 15, 2015 - Oregon Health & Science University today released an iPhone app designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time.

CTCA, Hospitals Duel Over Georgia CON Law

10/15/2015 12:00 pm

(Atlanta Business Chronicle) Oct 13, 2015 - Georgia health officials should remove a cap on in-state patients served by Cancer Treatment Centers of America (CTCA) so its hospital in Newnan can serve more Georgians suffering from cancer, CTCA officials said Tuesday.

ASCO Establishes New Fellowship Program to Boost Cancer Care Expertise in Young Oncologists; Application Period Opens October 15

10/15/2015 12:00 pm

(ASCO) Oct 15, 2015 - The American Society of Clinical Oncology (ASCO) has launched a new fellowship program that aims to provide physicians with the necessary skills to shape cancer policy.

Special Class of T Cells Shown to Both Attack Cancer Cells and Enlist Other Immune Cells

10/15/2015 11:05 am

(RPCI) Oct 15, 2015 - The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer’s offenses.

Cerulean Announces Completion of Enrollment of Randomized Phase 2 Trial of CRLX101 in Combination with Avastin® in Relapsed Renal Cell Carcinoma

10/15/2015 11:05 am

(Morningstar) Oct 15, 2015 - Cerulean Pharma Inc. today announced completion of enrollment of a randomized Phase 2 trial of its lead NDC, CRLX101, in combination with Avastin®, in third- and fourth-line relapsed renal cell carcinoma (RCC).

Delcath Announces First Patient Treated In ICC Cohort Of Global Phase 2 HCC Trial Program

10/15/2015 11:05 am

(Delcath Systems) Oct 15, 2015 - Delcath Systems, Inc. announces that the first treatment with the Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT) has been performed in the intrahepatic cholangiocarcinoma (ICC) cohort of the Company's global Phase 2 clinical trial program for treatment of patients with unresectable hepatocellular carcinoma (primary liver cancer or HCC) and ICC.

Nordic Nanovector Adapts Clinical Development Plan for Betalutin® in Follicular Lymphoma

10/15/2015 11:05 am

(Nordic Nanovector) Oct 15, 2015 - Nordic Nanovector ASA announces that it has taken the decision to revise its clinical development plan for Betalutin®, its lead product candidate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma.

Penn Bioethicist Calls on Researchers for More Evidence-Based End-of-Life Care Programs

10/15/2015 11:05 am

(Penn Medicine) Oct 15, 2015 - End-of-life program approvals should more closely mirror drug approval process, author says.

Beth Israel Deaconess Medical Center Names Manuel Hidalgo, MD, PhD, Clinical Director of the Cancer Center and Chief of Hematology-Oncology

10/15/2015 11:05 am

(BIDMC) Oct 14, 2015 - Manuel Hidalgo, MD, PhD, an internationally respected oncologist whose groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer, has been named Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC).

Argos Therapeutics Announces Formation of Scientific Advisory Board

7/21/2015 05:05 pm

(Argos Therapeutics) July 21, 2015 - Inaugural members include distinguished oncologists and immunologists to provide perspectives in research and development of individualized immunotherapies for the treatment of cancer.

Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003

7/15/2015 04:42 pm

(TheStreet) July 15, 2015 - Fully personalized immunotherapy is being evaluated in combination with standard targeted therapy for the treatment of newly diagnosed metastatic renal cell carcinoma (mRCC).

France Banned AB Science Drug Studies Because of Side Effects

7/9/2015 12:00 pm

(Bloomberg) July 8, 2015 - French regulators in 2012 prohibited biotechnology company AB Science from conducting nine clinical trials of its experimental drug in non-life-threatening illnesses because of the treatment's side effects.

U.S. Melanoma Rate Is Now Double What It Was 30 Years Ago

6/3/2015 10:04 am

(Los Angeles Times/Science Now) June 2, 2015 - The incidence of melanoma in the U.S. has doubled in the last 30 years, a new CDC report says.

Argos Therapeutics Provides Update on Enrollment Progress for Ongoing Pivotal Phase 3 ADAPT Clinical Trial

5/14/2015 06:22 pm

(Argos) May 13, 2015 - Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that more than 1,000 tumor samples have been collected and approximately 400 eligible patients have been randomized to the company's ongoing, pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).

US Proposal Would Greatly Expand Transparency of Clinical Trials

11/20/2014 05:01 am

(Forbes) Nov 19, 2014 - The US Department of Health and Human Services today proposed new rules that would greatly expand the number of clinical trials that companies and researchers are required to report.

HPV Test Better Than Pap for Assessing Cervical Cancer Risk: Study

7/21/2014 06:00 am

(Reuters Health) July 18, 2014 - Testing for human papillomavirus (HPV) may be the best way to know whether a woman is at risk of developing cervical cancer in the near future, according to a new study.

Roche Skin Cancer Drug Meets Main Goal in Combination Study

7/14/2014 01:04 am

(Reuters) July 14, 2014 - An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday.

Treatment With AGS-003 and Sunitinib Associated With Doubling of Expected Survival in Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)

6/2/2014 01:03 pm

(Yahoo! Finance) June 2, 2014 - Argos Therapeutics, Inc announced updated results from a completed phase 2 study highlighting the long-term survival observed in patients treated with sunitinib combined with AGS-003, the company's investigational fully personalized immunotherapy for cancer.

Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy

9/24/2013 04:33 pm

(MENAFN.COM) Sep 24, 2013 - The Phase 3 ADAPT clinical study is evaluating AGS-003, an investigational, fully personalized immunotherapy being examined in combination with standard targeted drug therapy to determine its potential to extend the overall survival in newly-diagnosed, unfavorable risk metastatic renal cell carcinoma (mRCC) patients.

Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy

9/24/2013 11:03 am

(MENAFN.COM) Sep 24, 2013 - The Phase 3 ADAPT clinical study is evaluating AGS-003, an investigational, fully personalized immunotherapy being examined in combination with standard targeted drug therapy to determine its potential to extend the overall survival in newly-diagnosed, unfavorable risk metastatic renal cell carcinoma (mRCC) patients.